• Vidac Pharma Holding shareholders passed all resolutions at its annual general meeting held on Oct. 4, 2026.
• Annual report and audited consolidated financial statements for the year ended Dec. 31, 2025 were received.
• Directors were reappointed.
• Strategy to partner with Eutopos Pharma for fundraising, development, commercialization in Europe won backing; no definitive license agreement was confirmed executed.
• Board authority renewed to allot shares or grant subscription or conversion rights up to an aggregate nominal amount of GBP 10,694,620.
• Statutory pre-emption rights were disapplied within specified limits.
• Capitalization of up to GBP 5 million from specified reserves was authorized to pay up shares issued under the authorities.
• MHA Audit Services was reappointed as auditor; directors authorized to set its remuneration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vidac Pharma Holding plc published the original content used to generate this news brief via pressetext (Ref. ID: 202610040435PRESSTXTEUPR____28256265A9712505667BD3198D120D1) on October 04, 2026, and is solely responsible for the information contained therein.